Vaxart, Inc. Restructuring and Related Cost, Cost Incurred to Date
Vaxart, Inc. (VXRT) had Restructuring and Related Cost, Cost Incurred to Date of $4.07 million as of 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Notes
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2022-02-24
- 2021-12-31: Restructuring and Related Cost, Cost Incurred to Date $4.07M.
- 2020-12-31: Restructuring and Related Cost, Cost Incurred to Date $4.07M.
- 2020-09-30: Restructuring and Related Cost, Cost Incurred to Date $4.07M.
- 2020-06-30: Restructuring and Related Cost, Cost Incurred to Date $5.02M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2021-12-31 | $4.07M 10-K · filed 2022-02-24 |
| 2020-12-31 | $4.07M 10-K · filed 2021-02-25 |
| 2020-09-30 | $4.07M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $5.02M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $4.98M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |